Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-VERSE AD: Idarucizumab for Dabigatran Reversal
NCT02104947Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2014
- Primary completion
- Jul 2016
- Modality
- Antibody Fragments
- Countries
- 33
01
Overview
A Phase 3 trial of idarucizumab in hemorrhage, sponsored by Boehringer Ingelheim. Started May 2014; status: completed.
02
Drugs
idarucizumab
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT02104947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02104947.